The news on January 4th, the news of the National Medical Insurance Bureau, recently, the market supervision department has adapted the sulfuric acid in the first biochemical pharmaceutical Co., Ltd. (hereinafter referred to as the first biochemistry of the first medicine) of the drug No. 1 Biochemical Pharmaceutical Co., Ltd.Active punishment for the dominance of the bacterial B market and the implementation of unfair high -priced sales preparations.According to the fact that the National Medical Insurance Administration and the prices checked by relevant departments, the prices and highs of the relevant departments have interviewed the first biochemistry of the medicine, supervised to further correct unreasonable high prices, eliminate the high space of drug prices, and eliminate adverse effects.After interviews, the price of the first biochemistry of the drug will be further reduced from 270 yuan/branch to 123 yuan/branch, and the stable supply will be reduced from 270 yuan/branch to 123 yuan/branch.
In the first half of 2023, the relevant departments found that the first biochemistry of the drug was suspected of increasing the cost of raw materials with three companies including Wuhan Huihai Pharmaceutical, Wuhan Kodo Pharmaceutical, and Hubei Minkang Pharmaceutical.The price of polypholin B hanging sulfurin in injection is illegally lifted to 2303 yuan/branch, and it is sold at home at a dozens of times higher than the foreign selling price. In just 5 years, the annual sales amount is achievedFor more than 100 million yuan, obtain huge improper benefits.After receiving the clue of the relevant departments, in order to avoid unreasonable high prices and continuously damage the legitimate rights and interests of patients, the State Medical Insurance Administration intervened in advance, and first interviewed the first biochemistry in the medicine in June 2023.After reminding, the company promised that the price of polyphonin B hanging sulfurine B hanging nets in various places will be reduced from 2303-2918 yuan per branch to 270 yuan, and it is promised to further reduce the hanging network according to the survey situation and the actual procurement of the raw and drug drugs in the future.price.Recently, after the relevant violations of laws and regulations were verified, the State Medical Insurance Bureau interviewed the first biochemistry of the medicine for the second time, and urged the performance of price rectification commitments.After two interviews, the price of polyphonin B hanging sulfuric acid sulfate B hanging nets in injection further reduced to 123 yuan/branch, a cumulative decrease of more than 95.8%. According to the amount of 2022, the drug is expected to reduce the cost of more than 3.8 billion for the annual medication.Yuan.At the same time, the first biochemistry of the medicine actively carried out self -examination and self -correction, actively transformed the sales model, eliminated the intermediate links of the procurement of raw materials and the virtual increase in drug circulation, and actively reduced the sulfate sulfate sour protein injection.The price decreases by 25.5%.
The National Medical Insurance Bureau has always supported pharmaceutical companies with high -quality, effective and affordable pharmaceutical products to provide people through research and development innovation and consistent evaluation.In return, it also advocates that pharmaceutical companies' integrity and legal operation and pricing. The truth is to reflect the cost of production, sales costs and corporate profits, and resolutely oppose various forms of virtual cost costs and cash out "gold sales" behavior.
Since the beginning of 2023, in response to the problems of some drug monopoly and sales of some pharmaceuticals, cost increase costs, and lack of rise, the State Medical Insurance Bureau has continued to strengthen the normalized supervision of drug prices, comprehensively use monitoring, early warning, inquiry and interviews, credit evaluation, credit evaluation, Information disclosure and other means, effectively and effectively deal with a batch of problems such as the price of the drug drugs and the rise in the price of the preparations. A total of 23 companies interviewed the enterprises throughout the year, involving 30 varieties, and the average price reduction of drugs exceeded 40%.At present, the State Medical Insurance Bureau is actively promoting the rectification work of the cost of manufacturing costs for some pharmaceutical consumables transferred by relevant departments.Price collaboration and governance, promote fairness, integrity, transparent and balanced price between regional prices, promote the establishment of a unified market in the field of pharmaceuticals, promote fair market competition, and strive to keep good drug prices for the people.
